Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response (Q42232786)

19 October 2017

Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response (English)

1 reference

19 October 2017

1 reference

1 reference

7

1 reference

19 October 2017

Daniel Yee-Tak Fong

5

0 references

Ching-Lung Lai

object named as

Ching-Lung Lai

11

0 references

Ivan Fan Ngai Hung

10

object named as

Ivan Fan-Ngai Hung

1 reference

19 October 2017

4

Yasuhito Tanaka

1 reference

19 October 2017

Danny Ka-Ho Wong

1

1 reference

19 October 2017

Malgorzata Kopaniszen

2

1 reference

19 October 2017

Katsumi Omagari

3

1 reference

19 October 2017

Wai-Kay Seto

6

1 reference

19 October 2017

Fung-Yu Huang

8

1 reference

19 October 2017

An-Ye Zhang

9

1 reference

19 October 2017

Man-Fung Yuen

12

1 reference

19 October 2017

language of work or name

English

0 references

publication date

8 March 2014

1 reference

Journal of Infectious Diseases

19 October 2017

1 reference

19 October 2017

210

1 reference

19 October 2017

701-707

1 reference

19 October 2017

5

1 reference

Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response

19 October 2017

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

Identification of HBV DNA sequences that are predictive of response to lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

Variant of hepatitis B virus with primary resistance to adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

Phenotypic assay of a hepatitis B virus strain carrying an rtS246T variant using a new strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

Structural basis of HIV-1 resistance to AZT by excision

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

Self-organized criticality

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance and Clinical Safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU133

21 January 2018

Identifiers

DOI

10.1093/INFDIS/JIU133

1 reference

19 October 2017

1 reference